Press Release Jun 14 2021
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This approval allows NATCO's marketing partner to launch the generic version of KYPROLIS in the U.S. market. The company expects to benefit from marketing exclusivity for certain strengths of the product upon launch. The press release also mentions a settlement agreement related to the product's litigation, allowing for a future launch date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release May 22 2021
- Press Release May 21 2021
- Press Release May 17 2021
- Press Release May 03 2021
- Press Release Apr 26 2021
Later from NATCO Pharma
- Press Release Jul 07 2021
- Press Release Aug 03 2021
- Press Release Aug 20 2021
- Press Release Sep 02 2021
- Press Release Oct 01 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma